Related Experiment Video
Updated: Jun 29, 2025
08:05
Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
7.8K
Lipocalin-2: a novel potential therapy for GVHD
1Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Trends in Immunology
|March 28, 2024
Summary
Lipocalin-2 (LCN2) may reverse intestinal damage in allogeneic hematopoietic stem cell transplantation (allo-HCT). Studies show LCN2 protein administration prevented graft-versus-host disease (GVHD) progression in mouse models.
Area of Science:
- Immunology
- Gastroenterology
- Hematology
Background:
- Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a life-saving procedure.
- Graft-versus-host disease (GVHD) remains a significant complication, particularly affecting the intestines.
- The precise regulatory mechanisms of intestinal GVHD are not fully understood.
Purpose of the Study:
- To investigate the role of lipocalin-2 (LCN2) in regulating intestinal GVHD.
- To determine if LCN2 can mitigate GVHD progression and associated tissue damage.
Main Methods:
- Utilized mouse models of allo-HCT.
- Administered recombinant LCN2 protein after the onset of GVHD symptoms.
Main Results:
- Recombinant LCN2 protein administration effectively prevented the progression of GVHD.
- LCN2 demonstrated potential in reversing existing intestinal tissue damage caused by GVHD.
Conclusions:
- Lipocalin-2 (LCN2) emerges as a novel regulator of intestinal GVHD.
- LCN2 holds therapeutic potential for reversing tissue damage and managing GVHD post-allo-HCT.
